Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;49(5):1065-1067.
doi: 10.1007/s15010-021-01621-w. Epub 2021 May 10.

Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol

Iacopo Vellere #  1 , Lucia Graziani #  1 , Marta Tilli #  1 , Antonia Mantella  1 , Irene Campolmi  2 , Jessica Mencarini  2 , Beatrice Borchi  2 , Michele Spinicci  1   2 , Alberto Antonelli  1   3 , Gian Maria Rossolini  1   3 , Alessandro Bartoloni  1   2 , Lorenzo Zammarchi  4   5
Affiliations
Comment

Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol

Iacopo Vellere et al. Infection. 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant disclosures for this article.

Comment on

References

    1. Marchese V, et al. Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection. 2020 doi: 10.1007/s15010-020-01522-4. - DOI - PMC - PubMed
    1. The Recovery Collaborative Group Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020;55455:5–6. doi: 10.1056/nejmoa2021436. - DOI - PMC - PubMed
    1. The REMAP-CAP Investigators Interleukin-6 receptor antagonists in critically ill patients with Covid-19—preliminary report. N Engl J Med. 2021 doi: 10.1056/NEJMoa2100433. - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-1645. PMID: 33933206; PMCID: PMC8084355. 10.1016/S0140-6736(21)00676-0 - PMC - PubMed
    1. Jamilloux Y, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19:102567. doi: 10.1016/j.autrev.2020.102567. - DOI - PMC - PubMed

LinkOut - more resources